<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02689921</url>
  </required_header>
  <id_info>
    <org_study_id>MZ2016006</org_study_id>
    <secondary_id>ML30001</secondary_id>
    <nct_id>NCT02689921</nct_id>
  </id_info>
  <brief_title>NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer</brief_title>
  <acronym>NEOADAPT</acronym>
  <official_title>A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Midwestern Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Midwestern Regional Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single-arm, phase II study of 32 evaluable patients treated with
      NEOADjuvant Aromatase inhibitor and Pertuzumab/Trastuzumab (NEOADAPT) without chemotherapy
      for hormone receptor positive (HR+), [i.e. Estrogen Receptor positive (ER+) and/or
      Progesterone Receptor positive (PR+)] HER2+ localized, non-metastatic stage I - IIb breast
      cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of Pathological Response</measure>
    <time_frame>One year</time_frame>
    <description>The presence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy. Pathological complete response (pCR) is defined as the absence of residual invasive cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment</measure>
    <time_frame>One year</time_frame>
    <description>Median number of days between Day 0 (first treatment of trastuzumab and pertuzumab) and three weeks after the last dose of neoadjuvant trastuzumab and pertuzumab on treatment protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of Radiographic Response</measure>
    <time_frame>Assessed every 12 weeks up to one year</time_frame>
    <description>Change in dimensions (millimeters) of target lesions (along long axis) and non-target lesions (along long axis for non-lymphatic lesions and short axis for lymph nodes) as observed by Magnetic Resonance Imaging and quantified by modified RECIST 1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of Left Ventricular Ejection Fraction (LVEF)</measure>
    <time_frame>Assessed every 12 weeks up to one year</time_frame>
    <description>Determination of cardiac function as measured by echocardiogram or multi-gated acquisition scan (MUGA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mammaprint Genomic Analysis</measure>
    <time_frame>One year or up to 3 months after definitive surgery</time_frame>
    <description>Mammaprint will estimate the risk level of the subject's tumor.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an aromatase inhibitor for the duration of the study [exemestane (tablet, oral, 25 mg/day), letrozole (tablet, oral, 2.5 mg/day) or anastrozole (tablet, oral, 1 mg/day)]. Premenopausal subjects will receive leuprolide acetate (11.25 mg, intramuscular injection, 3-month intervals).
Pertuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 840 mg, infused over 60-90 minutes; subsequent cycles: 420 mg, infused over 30-60 minutes).
Trastuzumab will be given by intravenous infusion in 3-week cycles until disease progression (Cycle 1 Day 0: 8 mg/kg, infused over 60-90 minutes; subsequent cycles: 6 mg/kg, infused over 30-60 minutes)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Aromatase inhibitor</description>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Aromatase inhibitor</description>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Aromatase inhibitor</description>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Luteinizing Hormone-Releasing Hormone agonist</description>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Monoclonal antibody (HER2/neu receptor antagonist)</description>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <other_name>Perjeta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Monoclonal antibody (HER2/neu receptor antagonist)</description>
    <arm_group_label>Neoadjuvant Biological Therapy</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide signed, written informed consent

          -  Histologically or cytologically confirmed non-metastatic adenocarcinoma of the breast
             (stage I-II)

          -  Candidate for curative-intent treatment

          -  ER+ and/or PR+ and HER2-positive (Fluorescence In Situ Hybridization-positive or 3+ by
             Immunohistochemistry staining)

          -  Life expectancy greater than 5 years

          -  Left Ventricular Ejection Fraction &gt; 50% at baseline (within 30 days of day 0)

          -  Eastern Cooperative Oncology Group performance status ≤2

          -  Absolute Neutrophil Count &gt;1000/µL

          -  Platelets ≥50,000/µL

          -  Hemoglobin &gt;8.0 g/dL,

          -  Creatinine ≤3.0 x upper limit of normal (ULN)

          -  Bilirubin ≤3.0 x ULN

          -  Aspartate aminotransferase or Alanine aminotransferase &lt;5.0 x ULN

          -  Negative serum pregnancy test for women &lt;12 months after the onset of menopause unless
             surgically sterilized

          -  Agreement by women of childbearing potential and male participants with partners of
             childbearing potential to use a &quot;highly effective&quot;, non-hormonal form of contraception
             or two &quot;effective&quot; forms of non-hormonal contraception by the patient and/or partner.

        Exclusion Criteria:

          -  Active infection

          -  Presence of known metastases (stage IV disease)

          -  Pregnant or lactating women

          -  Prior chemotherapy or radiation therapy for the primary breast cancer

          -  Concomitant malignancies or previous malignancies within the last 5 years except
             adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ
             of the cervix.

          -  History of significant cardiac disease, cardiac risk factors or uncontrolled
             arrhythmias

          -  Current severe, uncontrolled systemic disease (e.g., clinically significant
             cardiovascular, pulmonary or metabolic disease including diabetes, wound healing
             disorders, ulcers or bone fractures)

          -  Major surgical procedure or significant traumatic injury within 28 days prior to study
             treatment start or anticipated need for major surgery during the course of study
             treatment

          -  Current known infection with Human Immunodeficiency Virus (HIV), Hepatitis B virus
             (HBV) or Hepatitis C Virus (HCV)

          -  Receipt of intravenous antibiotics for infection within 14 days prior to receiving
             study treatment

          -  Current chronic daily treatment with corticosteroids (dose &gt;10 mg/day
             methylprednisolone equivalent) except inhaled steroids

          -  Known hypersensitivity to any of the study drugs

          -  Assessment by the investigator to be unable or unwilling to comply with the
             requirements of the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eugene Ahn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwestern Regional Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anjanette Sorensen, RN</last_name>
    <phone>847-7872-4701</phone>
    <email>Anjanette.Sorensen@CTCA-Hope.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eugene Ahn, MD</last_name>
    <phone>847-872-6189</phone>
    <email>Eugene.Ahn@CTCA-Hope.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quin Boynes</last_name>
      <phone>770-400-7080</phone>
      <email>Quin.Boynes@ctca-hope.com</email>
    </contact>
    <contact_backup>
      <last_name>Karen Rados</last_name>
      <phone>(770) 400-6629</phone>
      <email>Karen.Rados@ctca-hope.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ricardo Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Midwestern Regional Medical Center</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce Steinert, PhD</last_name>
      <phone>847-731-1648</phone>
      <email>bruce.steinert@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Ahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2016</study_first_submitted>
  <study_first_submitted_qc>February 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Midwestern Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Eugene Ahn</investigator_full_name>
    <investigator_title>Medical Oncologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

